Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer

Casey Williams, David Starks, Amy Krie et al.|Gynecologic Oncology|2019

Cited by 0